$DXC

American Century (NYSE: DXC) group discloses 6.4% beneficial stake in DXC

American Century entities filed an SEC Schedule 13G/A for DXC Technology Company. As of June 30, 2026, American Century ETF Trust reported 10,022,365 shares, 6.2% of the class, with sole voting and dispositive power. American Century Investment Management, American Century Companies, and Stowers Institute reported 10,436,267 shares, 6.4%.

Original reporting
Published Aug 14, 2026, 12:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 15, 2026, 2:47 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$DXC
Neutral
medium confidence
Mentioned
$DXC
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$DXCNeutralLow
01

Why it matters

The key new information is the reported beneficial ownership level and sole voting/dispositive power, which can matter for governance optics but is not, by itself, a catalyst.

02

Market read

This is an ownership transparency update. It may slightly influence sentiment around DXC’s shareholder base, but the article provides no operational or strategic trigger.

03

What to watch

Traders may want to check whether the filing is a new position versus prior holdings, and whether any separate 13D or activist communications exist, since the article only summarizes the 13G.

Relevance 4/10Novelty 4/10Timing: ownership disclosure dated June 30, 2026, reported Aug 14, 2026

Background

The article summarizes a Schedule 13G beneficial ownership disclosure by American Century entities for DXC Technology Company common stock as of June 30, 2026.

Company-level read

Ticker impact

$DXCNeutralMedium confidence
Context

American Century entities disclosed beneficial ownership of 10.44M DXC shares, 6.4% of the class, via a Schedule 13G filed for June 30, 2026.

Expected impact

Likely limited immediate impact; any effect would be indirect via sentiment around ownership concentration.

Evidence & confidence

Schedule 13G ownership disclosures are typically informational. The article provides stake size and voting/dispositive control but no stated intent to change strategy, pursue M&A, or force governance outcomes.

Market effects

Minimal. Large passive or semi-passive ownership changes rarely alter sector fundamentals without accompanying strategy or operational catalysts.

Minimal, US-focused disclosure with no stated cross-border transaction.

Low. No global deal, regulatory action, or operational change is described.

Counterpoint

A 6.4% stake could be a precursor to engagement or governance pressure, even if the filing itself does not state intent.

Key entities

  • DXC Technology Company

    Subject of the Schedule 13G beneficial ownership disclosure; American Century entities report 6.4% beneficial ownership as of June 30, 2026.

  • American Century ETF Trust

    Reports 10,022,365 shares, 6.2% of DXC common stock, with sole voting and dispositive power.

  • American Century Investment Management, Inc.

    Part of the group reporting 10,436,267 shares, 6.4% of the class, with sole voting and dispositive power.

  • American Century Companies, Inc.

    Part of the group reporting 10,436,267 shares, 6.4% of the class, with sole voting and dispositive power.

  • Stowers Institute for Medical Research

    Named as a reporting person in the group holding 10,436,267 shares, 6.4% of DXC common stock.

Related articles

$DXCMedAI 8/10

DXC (DXC) Q1 2027 Earnings Call Transcript

Thursday, July 30, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Roger Sachs President and Chief Executive Officer - Raul J. Fernandez Chief Financial Officer - Robert F. Del Bene TAKEAWAYS Total Revenue -- $3 billion, representing a 6.7% organic decline year over year. Adjusted EBIT Margin -- 5.0%, a decrease of 180 basis points year over year reflecting the anticipated revenue profile and seasonal factors.

$DXCMedAI 8/10

DXC’s (NYSE:DXC) Q2 CY2026 Earnings Results: Non

IT services provider DXC Technology (NYSE: DXC) met Wall Street’s revenue expectations in Q2 CY2026, but sales fell by 5.1% year on year to $3.00 billion. On the other hand, next quarter’s revenue guidance of $2.99 billion was less impressive, coming in 1.5% below analysts’ estimates. Its non-GAAP profit of $0.40 per share was 11.3% below analysts’ consensus estimates. Is now the time to buy DXC? Find out by accessing our full research report, it’s free.

$DXCMedAI 9/10

DXC Technology Co (DXC): Results of Operations and Financial Condition

DXC Technology Co (DXC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dxcfy27q1pressrelease.htm EX-99.1 Document Exhibit 99.1 DXC Technology Reports First Quarter Fiscal Year 2027 Results • Total revenue for Q1 FY27 of $3.00 billion, down 5.1% YoY, down 6.7% on an organic basis (1) • Q1 FY27 Bookings of $3.0 billion, up 5% YoY with a book

$DXCMed

Why is DXC Technology stock rallying today? By Investing.com

DXC Technology shares rose about 4.3% after the company said it partnered with ElevenLabs and participated in ElevenLabs’ $500 million Series D, valuing the AI firm at about $11 billion, according to DXC’s July 28, 2026 press release. The collaboration targets voice AI for service desk, training, and customer service. DXC’s Q1 FY2027 earnings are due July 30.